The powerful proprietary technologies, model systems, and platforms developed at ND Biosciences are based on more than 15 years of ground-breaking research at the lab of ND Biosciences’ co-founder, Prof. Hilal Lashuel, at the École Polytechnique Fédérale de Lausanne (EPFL). ND Biosciences has assembled a deeply experienced team in the field of neurodegenerative disease research and an exceptional network of collaborators and partners to build upon and translate these technologies to:
- Discover and preclinically validate novel therapeutics for neurodegenerative diseases (NDs), based on targeting relevant pathological conformations and attenuating processes related to different stages of disease progression
- Develop sensitive assays and imaging agents for early diagnosis, monitoring disease progression, and to support clinical trials and precision medicine for NDs
A Team with 35 years of combined experience in neurodegenerative disease research
Prof. Hilal Lashuel
Co-founder and CSO, is Associate Professor and Director of the laboratory of molecular chemical biology of neurodegeneration at the EPFL since 2005 (Website), and served as executive director of the Qatar Biomedical Research Institute (QBRI) (2014 – 2016). Prof. Lashuel is recognized globally as one of the key opinion leaders in the field of neurodegenerative diseases, with 185 publications in major journals, 5 patents, hundreds of invited lectures, and more than 21000 citations. Dr. Lashuel has received numerous scientific research grants and prestigious awards and was named “Young Global Leader” by the World Economic Forum (WEF), and as one of the “100 Outstanding Personalities” in the French-speaking part of Switzerland by the Swiss business magazine “L’Hebdo.”
Dr. Bilal Fares
Co-founder and director of R&D, completed his Ph.D. in biotechnology and bioengineering at the EPFL (Lashuel lab), where he developed the first preclinical model of Parkinson’s disease reproducing early stages of pathological protein aggregation in neurons. Through R&D experiences at prominent academic and industrial institutions across Switzerland, the USA, and the UK, Dr. Fares has over 10 years of experience in developing and managing international projects in the field of preclinical disease modeling and drug discovery for neurodegenerative diseases. Dr. Fares is also experienced in managing different aspects of biotech formation, operation, and business development through his current role at ND Biosciences, and recently completed a selective MBA program from Quantic, USA.
Head of biomarkers and diagnostic development, has been working on neurodegenerative disorders since 2006 when she investigated metabolic dysfunction in Huntington’s Disease. During her Marie Curie fellowship in Italy, she worked at different biotech companies as a scientist, senior scientist, and then as head of neuroscience lab and project leader, where she led efforts towards the development of ultrasensitive immunoassays for the detection and validation of post-translationally modified disease-causing proteins, as potential biomarkers for Huntington’s and Parkinson’s Disease. In these studies, Lara deployed different immuno-assay platforms, including ELISA, TR-FRET, MSD, and SMC, and she successfully led the establishment of several fully validated and published immuno-assays.
Lab manager and protein production specialist, is an R&D expert through diverse experiences in academia, industry, and biotech. Following her Masters in medical biology from the University of Lausanne in 2014, Marylin worked as scientific collaborator, and then as regional quality assurance manager at a leading international provider of diagnostic services. Through this position, Marylin gained valuable experience in planning and managing internal audits, surveillance of laboratory accreditation processes, and monitoring of internal documentation and management systems. Following this experience, Marylin joined the EPFL as an associate research scientist, where she mastered the ability to express, purify and characterize diverse proteins and antibodies. Marylin is currently managing ND Biosciences’ laboratory, and leading efforts for protein production and discovery.
Dr. Gabriella Saro
Research scientist, completed her Masters in molecular biotechnology at the University of Turin, and her PhD in neurobiology from the University of Fribourg. Initially, Dr. Saro specialized in neurodevelopment and then gained experience in electrophysiology, neurogenetics, sensation, and calcium signaling using different cellular and C. elegans models. During her studies, Dr. Saro developed and applied sophisticated live imaging assays based on the detection of single-cell calcium transients in cellular models, as well as microfluidic-coupled FRET-based imaging in C. elegans. Dr. Saro is currently leading ND Biosciences’ cellular screening and discovery efforts in the lab and is also developing novel cellular models of neurodegenerative diseases.